Shares of Emcure Pharmaceuticals declined 6 percent in Tuesday's trade following the announcement of Q4 FY26 results, with profit booking weighing on the stock. The stock settled 6 percent lower at ₹1,689 per share on the National Stock Exchange (NSE). According to reports from Moneycontrol, the company's standalone price-to-earnings (PE) ratio stood at 49.90, compared with the Nifty Pharma PE of 35.
Emcure Pharmaceuticals reported a 24 percent increase in consolidated net profit at ₹243.74 crore for the fourth quarter ended March 2026, driven by growth in its international business. As reported by Moneycontrol, the company had posted a consolidated net profit of ₹197.24 crore in the year-ago period. Consolidated revenue from operations in the quarter rose to ₹2,469.7 crore from ₹2,116.25 crore a year earlier. International business sales stood at ₹1,493 crore, up 25.7 percent year-on-year, supported by growth across markets, base business ramp-up and new launches.
For FY26, consolidated net profit rose to ₹941.27 crore from ₹707.47 crore in FY25, while consolidated revenue from operations stood at ₹9,203.54 crore as against ₹7,896 crore in the previous financial year. According to the regulatory filing, domestic business sales were at ₹977 crore, up 5.2 percent year-on-year, with the softer performance largely due to its Zuventus Healthcare Ltd portfolio and team reorganisation.
Commenting on the performance, Managing Director and CEO Satish Mehta said the company delivered strong financial performance in FY26, the first year of its five-year strategic plan, with over USD 1 billion in revenue and 16.6 percent growth. As reported by Moneycontrol, he emphasized that international markets showed robust momentum while domestic business recorded steady growth. The company's R&D pipeline in complex injectables and biosimilars remains a key driver of future value, with focus on sustainable growth and margin expansion.
The company's board has approved the re-appointment of Mehta as Managing Director for a further period of five years from April 1, 2027, subject to shareholders' approval. The board has also recommended a final dividend of ₹3.6 per fully paid-up equity share of ₹10 each for the financial year ended March 2026, subject to shareholders' approval. Total expenses in the fourth quarter increased to ₹2,142.82 crore from ₹1,849.7 crore in the corresponding period last fiscal.
